NCCN Guidelines Integrated into CancerIQ Platform to Arm Providers to Act on Results of Genetic Tests
Adventist Health to expand use of CancerIQ Platform across 265 ambulatory clinics
PLYMOUTH MEETING, Pa. and CHICAGO, March 21, 2019 /PRNewswire-PRWeb/ -- The National Comprehensive Cancer Network® (NCCN®) is collaborating with CancerIQ, Inc. to integrate NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) into the CancerIQ Platform to equip providers to manage patients according to their risk-based care plan, navigate patients to the right care, and offer ongoing engagement to reduce risk over time.
"As we continually enhance genetic testing guidelines based on the growing body of research, we must first ensure providers are prepared to take appropriate, preventive action based on the results," said Robert W. Carlson, MD, Chief Executive Officer, NCCN. "We are enthusiastic about the integration of the NCCN Guidelines® for Breast Cancer Screening and Diagnosis and Colorectal Cancer Screening into the CancerIQ Platform, thereby increasing the availability of evidence-based clinical decision support to ensure patients in all healthcare settings receive high-quality care."
With the costs of a multigene panel as low as $250 and often covered by insurance, the volume of genetic testing only will continue to grow. More patients with genetic testing results that need interpretation will run into the barrier of the severe shortage of genetic counselors. Many providers lack the genetics training needed to effectively counsel patients on the risks they face.
The recommendations from the NCCN Guidelines are now woven into two cloud-based CancerIQ modules: CancerIQ Specialist and CancerIQ Manager, the second and third modules in the CancerIQ Platform. While genetics providers can determine appropriate care plans in CancerIQ Specialist, CancerIQ Manager is important for providers with less genetic counseling expertise who will be managing patients over time. CancerIQ Manager streamlines the management of high-risk patients, from coordinating with other providers to engaging patients to carry out the care plan.
"In this increasingly complex world of genetics, clinicians need guidance to act on that genetic information appropriately," said Feyi Olopade Ayodele, CEO of CancerIQ. "That's why CancerIQ worked to become the only software vendor that is a licensee of the NCCN guidelines for management of hereditary cancer. By embedding the algorithms from the NCCN Guidelines, we can eliminate both undertreatment and overtreatment, equip doctors to engage in shared-decision making with patients, and support care teams to take action on genetic testing results."
The NCCN Guidelines are the recognized standard for clinical policy in cancer care and are the most thorough and most frequently updated clinical practice guidelines available in any area of medicine. For more information about the use of NCCN Content in Health Information Technology, visit NCCN.org/HIT.
Adventist Health, Roseville, Calif., has used the CancerIQ platform and was pivotal to the development of the CancerIQ Manager. Adventist Health started with the software in several clinics and is expanding its use across its 265 ambulatory clinics.
"Through our partnership with CancerIQ, we're helping providers to manage high-risk patients," said Candace Westgate, MD, director of the AHEAD Program at Adventist Health, a population hereditary cancer risk assessment initiative. "Our multidisciplinary team is making sure patients receive the preventive care they need when they need it. That is what will ultimately drive early detection and prevention made possible through genetic testing."
CancerIQ Specialist and CancerIQ Manager provide a more comprehensive level of evaluation and management than CancerIQ's basic high-risk triage solution: the CancerIQ Screening Toolkit. To further streamline risk assessment and workflow, CancerIQ recently announced new partnerships with Cordata Healthcare Innovations, MRS Systems, Inc., and PenRad Technologies, Inc. at the National Consortium of Breast Centers 29th annual https://www..breastcare.org/welcome-to-the-annual-national-interdisciplinary-breast-center-conference/ [Interdisciplinary Breast Center Conference __title__ Interdisciplinary Breast Center Conference] in Las Vegas.
About National Comprehensive Cancer Network (NCCN)
The National Comprehensive Cancer Network® (NCCN®) is a not-for-profit alliance of 28 leading cancer centers devoted to patient care, research, and education. NCCN is dedicated to improving and facilitating quality, effective, efficient, and accessible cancer care so patients can live better lives. Through the leadership and expertise of clinical professionals at NCCN Member Institutions, NCCN develops resources that present valuable information to the numerous stakeholders in the health care delivery system. By defining and advancing high-quality cancer care, NCCN promotes the importance of continuous quality improvement and recognizes the significance of creating clinical practice guidelines appropriate for use by patients, clinicians, and other health care decision-makers around the world. Clinicians, visit NCCN.org. Patients and caregivers, visit NCCN.org/patients. Media, visit NCCN.org/news. Follow NCCN on Twitter @NCCNnews and Facebook @National.Comprehensive.Cancer.Network.
About CancerIQ
CancerIQ's technology enables hospitals to identify, evaluate and manage entire patient populations based on individual genetic risk factors. By analyzing family history, running predictive risk models and automating NCCN guidelines, CancerIQ empowers community-based providers with the genetic expertise to prevent cancer or catch it early. The platform has been rapidly adopted by some of the top health systems in the country and fully integrates with genetics laboratories, EHRs, and specialty software vendors to streamline workflow, guide clinician decision making, achieve cost savings, and – most importantly – improve patient outcomes. Learn more about how CancerIQ is scaling the use of genetic testing to predict, preempt and prevent disease at Canceriq.com.
SOURCE The National Comprehensive Cancer Network®
Share this article